IRIS Institutional Research Information System - AIR Archivio Istituzionale della Ricerca

GUIDETTI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.424
NA - Nord America 2.671
AS - Asia 2.176
SA - Sud America 167
OC - Oceania 57
AF - Africa 33
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.530
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.588
DE - Germania 1.134
CN - Cina 1.016
GB - Regno Unito 956
IT - Italia 886
SG - Singapore 374
SE - Svezia 314
RU - Federazione Russa 206
JP - Giappone 189
IN - India 159
ES - Italia 150
FR - Francia 149
IE - Irlanda 116
BR - Brasile 112
UA - Ucraina 96
TR - Turchia 85
CH - Svizzera 82
KR - Corea 70
FI - Finlandia 68
NL - Olanda 61
ID - Indonesia 58
AU - Australia 54
CA - Canada 53
HK - Hong Kong 49
TH - Thailandia 42
DK - Danimarca 36
BE - Belgio 35
GR - Grecia 31
MX - Messico 27
PL - Polonia 23
CO - Colombia 21
VN - Vietnam 21
EU - Europa 20
AT - Austria 19
TW - Taiwan 18
IR - Iran 15
LB - Libano 15
CZ - Repubblica Ceca 14
PT - Portogallo 14
AR - Argentina 12
PE - Perù 12
PH - Filippine 12
IL - Israele 8
JO - Giordania 8
MA - Marocco 7
EG - Egitto 6
MY - Malesia 6
PK - Pakistan 6
SC - Seychelles 6
UZ - Uzbekistan 6
SA - Arabia Saudita 5
AZ - Azerbaigian 4
BG - Bulgaria 4
CL - Cile 4
EE - Estonia 4
HU - Ungheria 4
TN - Tunisia 4
HR - Croazia 3
NO - Norvegia 3
NZ - Nuova Zelanda 3
RO - Romania 3
SI - Slovenia 3
ZA - Sudafrica 3
CI - Costa d'Avorio 2
GH - Ghana 2
IQ - Iraq 2
LT - Lituania 2
LV - Lettonia 2
MK - Macedonia 2
NP - Nepal 2
PS - Palestinian Territory 2
UY - Uruguay 2
AL - Albania 1
BD - Bangladesh 1
BO - Bolivia 1
BS - Bahamas 1
CU - Cuba 1
DZ - Algeria 1
EC - Ecuador 1
GA - Gabon 1
GT - Guatemala 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
ME - Montenegro 1
MW - Malawi 1
PY - Paraguay 1
QA - Qatar 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
VE - Venezuela 1
Totale 9.548
Salva come PNG Salva come JPEG
Città #
Frankfurt am Main 806
Southend 799
Milan 317
Chandler 280
Singapore 244
Beijing 181
Seattle 139
Wilmington 133
Ashburn 125
Fairfield 124
Dublin 115
Princeton 99
Hangzhou 80
Ann Arbor 77
Council Bluffs 77
Nanjing 76
Dearborn 74
Houston 69
Jacksonville 67
Shanghai 64
Woodbridge 63
Jakarta 48
Santa Clara 47
Tokyo 47
Barcelona 46
Redwood City 44
Redmond 43
Bengaluru 42
Cambridge 39
Chicago 37
Guangzhou 36
New York 36
Serra 36
Helsinki 34
Des Moines 33
Hanover 31
Mountain View 30
Rome 30
Berlin 27
Los Angeles 27
Tianjin 27
Moscow 26
Somerville 26
Jinan 24
Lugano 23
Boardman 21
Paris 21
London 20
Nanchang 20
Madrid 19
Phoenix 19
Sakarya 19
San Diego 19
Shenyang 19
Andover 18
Bogotá 18
Fremont 17
Hong Kong 17
Zhengzhou 17
Brussels 16
Philadelphia 16
Southampton 16
São Paulo 16
Vienna 16
Wuhan 16
Naples 15
Sydney 15
Athens 14
Bangkok 14
Beirut 14
Boston 14
Brisbane 14
Chengdu 14
Falls Church 14
Fuzhou 14
Jiaxing 14
Melbourne 14
Munich 14
Nuremberg 14
Silver Spring 14
Chiang Mai 13
Dong Ket 13
Hyderabad 13
Toronto 13
Trieste 13
Zurich 13
Changsha 12
Hebei 12
Istanbul 12
Kunming 11
Rochester 11
Salamanca 11
Amsterdam 10
Atlanta 10
Bologna 10
Mumbai 10
Upper Marlboro 10
Verona 10
Auburn Hills 9
Belo Horizonte 9
Totale 5.645
Salva come PNG Salva come JPEG
Nome #
Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma 1.634
Topical prophylaxis of conjunctivitis induced by high-dose cytosine arabinoside 520
Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma 466
Outcome after chimeric antigen receptor (CAR) T-cell therapy failure in large B-cell lymphomas 406
High-dose chemotherapy followed by autologous transplantation may overcome the poor prognosis of diffuse large B-cell lymphoma patients with MYC/BCL2 co-expression 323
A Phase 2 multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy 235
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells 193
Phenotypic composition of commercial anti-CD19 CAR-T cells affects in vivo expansion and disease response in large B-cell lymphoma patients 190
Pomalidomide for the treatment of relapsed and refractory multiple myeloma 190
Use of recombinant human growth hormone (rhGH) plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizers 177
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA) 175
Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone (rhGH) 158
Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination: a phase I trial in metastatic melanoma 158
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion : an outpatient preparative regimen for autologous hematopoietic cell transplantation 157
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice 157
Interferon γ enhances the anti-myeloma activity of the fully human anti-HLA-DR monoclonal antibody 1D09C3 153
Dose-Adjusted Epoch and Rituximab for the treatment of double expressor and double hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome 152
A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis 149
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation : Life-threating Features Within the Early Post-engraftment Phase 148
Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with Defibrotide and recombinant human granulocyte colony-stimulating factor 147
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma 146
IFN-γ enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 145
Clinical protocol. Immunization of patients with malignant melanoma with autologous CD34+ cell-derived dendritic cells transduced ex vivo with a recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial 144
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 142
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®) 141
Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis 137
High response rate and manageable toxicity with an intensive, short-term chemotherapy program for Burkitt’s lymphoma in adults 125
Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor : an algorithm for the pre-emptive use of plerixafor 123
Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes? 120
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey 116
SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma 115
Dosimetry in myeloablative (90)Y-labeled ibritumomab tiuxetan therapy : possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. 114
Early Serum TARC Reduction Predicts Prognosis in Advanced-Stage Hodgkin Lymphoma Patients Treated with a PET-Adapted Strategy 110
Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma : long-term outcomes and graft-versus-host disease-free/relapse-free survival 106
Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia 103
Gene Abnormalities in Transplant Associated-Thrombotic Microangiopathy: Comparison between Recipient and Donor's DNA 102
Radioimmunotherapy and secondary leukemia : a case report 102
Detection of minimal residual disease in hematopoietic progenitor cell harvests : lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma 102
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma : long-term follow-up 101
Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma 99
COVID-19 and CAR-T cells: current challenges and future directions-a report from the EPICOVIDEHA survey by EHA-IDWP 99
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts 98
Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial 97
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 96
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 94
Methodological framework for radiomics applications in Hodgkin’s lymphoma 89
T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies 89
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma 87
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study 83
Resistance to proteasome inhibitors in multiple myeloma 80
Long-term results of autologous hematopoietic stem-cell transplantation after high-dose 90Y-ibritumomab tiuxetan for patients with poor-risk non-Hodgkin lymphoma not eligible for high-dose BEAM 75
Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti-CD19 chimeric antigen receptor T-cell efficacy 74
Phase II study of sorafenib in patients with relapsed or refractory lymphoma 65
Plerixafor 'on demand': results of a strategy based on peripheral blood CD34+ cells in lymphoma patients at first or subsequent mobilization with chemotherapy+G-CSF 63
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics 62
Timing of high dose methotrexate CNS prophylaxis in DLBCL : a multicenter international analysis of 1,384 patients 57
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry 54
Outcome of infection with omicron SARS-CoV-2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report 49
Cytokine secretion associated with the clearance of apoptotic bodies in renal cell carcinoma patients 43
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 39
Efficacy of antibody–drug conjugate brentuximab vedotin in treating Hodgkin’s lymphoma 32
Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant hematological malignancies: An Italian retrospective study 26
Inflammation and lymphoma: Therapeutic implications 24
Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post CD19-CAR-T: an EPICOVIDEHA survey 19
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022 11
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey 9
Interim-PET predicts progression-free survival in stage IV Hodgkin lymphoma treated with upfront brentuximab vedotin-AVD 1
Totale 9.896
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.864
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.864
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020272 0 0 0 0 0 0 0 0 145 79 27 21
2020/2021876 42 89 85 22 52 88 73 57 98 86 140 44
2021/20221.154 100 53 52 47 53 68 69 176 145 104 77 210
2022/20231.550 142 146 111 106 158 225 71 124 148 73 149 97
2023/20242.053 84 103 127 135 274 124 221 213 109 169 234 260
2024/20251.721 176 270 188 226 204 156 144 237 120 0 0 0
Totale 9.896